About DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals is a company based in Seoul (South Korea) founded in 1984. The company has 365 employees as of December 31, 2024. DAE HWA Pharmaceuticals offers products and services including Prescription Drugs, OTC Drugs, and Health Functional Foods. DAE HWA Pharmaceuticals operates in a competitive market with competitors including PharmaJet, Arecor, Suono Bio, Renovis and Ensysce, among others.
- Headquarter Seoul, South Korea
- Employees 365 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Dae Hwa Pharm Co., Ltd.
-
Annual Revenue
$101.31 M (USD)5.69as on Dec 31, 2024
-
Net Profit
$360.34 K (USD)146.21as on Dec 31, 2024
-
EBITDA
$8.79 M (USD)68.64as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
365
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals is a publicly listed company on the KRX with ticker symbol 067080 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals offers a comprehensive portfolio of products and services, including Prescription Drugs, OTC Drugs, and Health Functional Foods.
Medications for treatment under medical supervision.
Over-the-counter remedies for common health issues.
Supplements promoting health and wellness benefits.
Funding Insights of DAE HWA Pharmaceuticals
Detailed funding history for DAE HWA Pharmaceuticals
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DAE HWA Pharmaceuticals
Investment portfolio details for DAE HWA Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DAE HWA Pharmaceuticals
Detailed financials for DAE HWA Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dae Hwa Pharmaceuticals Comparisons
Peer comparison for DAE HWA Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PharmaJet, Arecor, Suono Bio, Renovis and Ensysce, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of needle-free injection technology
|
|
| Locked | Locked | Locked |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
|
| Locked | Locked | Locked |
Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract
|
|
| Locked | Locked | Locked |
Drugs for neurological diseases are discovered and developed.
|
|
| Locked | Locked | Locked |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
|
| Locked | Locked | Locked |
Provider of a proprietary platform for gene therapy
|
Detailed competitors of DAE HWA Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dae Hwa Pharmaceuticals
Complete news archive for DAE HWA Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals was founded in 1984.
DAE HWA Pharmaceuticals is headquartered in Seoul, South Korea.
As of Dec 31, 2024, the latest employee count at DAE HWA Pharmaceuticals is 365.
Annual revenue of DAE HWA Pharmaceuticals is $101.31M as on Dec 31, 2024.
DAE HWA Pharmaceuticals was founded in 1984 in Seoul, South Korea, and operates in the pharmaceutical sector. Focus is placed on reformulating existing drugs through transdermal and oral delivery methods. The lead product, DHP 107, an oral paclitaxel formulation, is undergoing phase III trials for cancer treatment. A lipid-based oral formulation has been developed, with plans to address NSAIDs, antihistamines, antidepressants, and additional medications.
DAE HWA Pharmaceuticals's top competitors include Oxular, PharmaJet and Splice Bio.
DAE HWA Pharmaceuticals offers Prescription Drugs, OTC Drugs, and Health Functional Foods.
Yes, DAE HWA Pharmaceuticals is publicly traded on KRX under the ticker symbol 067080.
The ticker symbol of DAE HWA Pharmaceuticals is 067080 on KRX.